The company has been hoping that CagriSema can improve on the efficacy of its single-agent obesity drug Wegovy (semaglutide) and help defend its obesity franchise against Eli Lilly – whose dual ...
Novo Nordisk’s phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema ... its lead incretin candidate CT-388, a dual GLP-1/GIP receptor agonist, as a ...
This week, Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema ... lead incretin candidate CT-388, a dual GLP-1/GIP receptor agonist, as ...
REDEFINE 2 is a 68 weeks efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The ...
Novo Nordisk confirmed this in the REDEFINE-1 phase 3 trial, where CagriSema (a combination of a GLP-1 agonist semaglutide and amylin analog cagrilintide) showed superior weight loss to its ...
PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support Patch Collection—a targeted solution designed to complement individuals ...
The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo Nordisk’s CagriSema which has an amylin analog as a “performance enhancer” on top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback